REGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT
Thursday, July 25, 2002 1 min read
Key Takeaway: REGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT
Full Press Release Details
REGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT.